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Abstract 
 
 
In this review we discuss how sex steroids and prolactin affect regulation and responsiveness of 
B and T cells. Sex hormones exert profound effects on several physiological processes of non- 
reproductive tissues. In the immune system, several studies with experimental models for SLE 
have shown a noticeable pro-inflammatory role for ERα, contributing to disease development 
reflected in proteinuria and renal pathology. On the other hand, ERβ appears to have an anti- 
inflammatory and immunosuppressive  effect.  Estrogen/ERα  signaling  induced  an  increase 
of Th17 cells in lymph nodes as well as the expression of its correspondent chemokine receptor 
CCR6 during collagen induced arthritis acute phase. High levels of anti- DNA antibodies and 
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increased mortality was observed when given high E and prolactin doses to NZB/NZW mice, as 
compared with mice receiving low E and prolactin doses, or high E and low prolactin doses. 
Intracellular progesterone receptors have been detected in TCD4
+ 
cells but in contrast as 
observed with ERs, it suppresses T cell dependent responses. Progestagen administration on 
female NZB/NZW mice decreased anti DNA IgG, improved survival, decreased 
glomerulonephritis and proteinuria. 
 
 
 
 
 
 
Introduction 
 
It is well known that autoimmune diseases are triggered by an immune response raised 
by the body directed towards its own tissues or cellular components; however, their etiology 
remains unknown. Although advances have been reported in the last decade in relation to their 
mechanisms, specific and effective therapies for autoimmune disorders have not yet been 
developed [1-4]. Currently, it is postulated that multiple factors participate in the onset of 
autoimmune diseases including genetic, environmental, infectious and hormonal components 
that confer greater susceptibility but are not determinant for their development [5-7]. The high 
incidence of autoimmune diseases in females versus males suggests that female hormonal 
homeostasis is a very important risk factor [8]. 
Sex hormones exert profound effects on several physiological processes of non- 
reproductive tissues. In the immune system, sex hormones have several activities, such as 
modulation of cytokine production by lymphocytes, cytokine receptor expression, and 
activation of effector immune cells [9]. By modifying dendritic cells (DCs) function, E (E) 
could alter T cell proliferation [10]. In contrast, incubation of DCs with Progesterone (Pg) 
decreases T cell priming and prevents the upregulation of co-stimulatory molecules after 
stimulation with Toll-like receptor 3 (TLR3) ligands[11]. In relation to hormonal status, it has 
been reported that a certain subset of Systemic Lupus Erythematosus (SLE) patients showed 
high prolactin levels, which have also been associated to disease activity [12, 13]. In this 
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review, we discuss recent data relative to the role of E, prolactin and progesterone in T and B 
cells function in immunity and autoimmune disorders. 
 
 
 
 
Estrogens and T cells 
 
 
Estrogens have a complex role in inflammation [14] and most of their effects are mediated by 
two specific intracellular receptors, i.e., E receptor (ER) α and β, which function as ligand- 
activated nuclear transcription factors producing genomic effects [15]. ERα and β are the 
products of different genes (ESR1 and ESR2, respectively) and in the human, are located on 
different chromosomes (locus6q25.1 and locus 14q23-24.1, respectively) [16, 17]. Human ERα 
and ERβ are modular proteins that belong to the nuclear receptor protein family, with a structure 
that can be divided into common regions, named A/B, C, D, E, and F. These regions participate 
in the formation of independent and interacting functional domains: the N-terminal 
transactivation domain, the DBD (DNA-binding domain), the dimerization domain(s), the 
nuclear localization sequence (NLS), and the LBD (ligand-binding domain) [18-20]. The A/B 
region or the N-terminal transactivation domain of ERs is involved in protein–protein 
interactions [21] and in transcriptional activation of target-gene expression [19, 21]. Also, it 
contains the activation function-1 (AF-1) domain and several phosphorylation and sumoylation 
sites [18]. The AF-1 domain binds, directly or via co-activators/co-repressors, to some parts of 
the primary transcription machinery [22]. The DBD plays an important role in receptor 
dimerization and binding of specific DNA sequences [20]. The C-terminal E/F region of ERs 
include the LBD, the AF-2 domain, and part of the nuclear localization region (NLS) [20, 23]. 
 
ERα and ERβ differ markedly in their tissue distribution that includes immune cells [15, 24, 25]. 
The relative expression of one ER subtype over the other might change E effects, promoting or 
dampening inflammation [14]. Several studies with experimental models for SLE developed in 
mice have showed a noticeable pro-inflammatory role for ERα, contributing to disease 
development reflected in proteinuria and renal pathology [26-28]. On the other hand, ERβ 
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appears to have an anti-inflammatory and immunosuppressive effect on these mice and 
application of the ERβ-selective agonist diarylpropionitrile (DPN) starts a reduction of 
autoantibody production and a decline of albuminuria [27]. In fact, a significantly lower 
expression of ERβ in T cells from patients with SLE compared with healthy controls [29] has 
been reported. Similarly, a significant reduction of ERβ expression in peripheral blood T 
lymphocytes from Crohn disease and ulcerative colitis patients with active disease as compared 
to those in remission and healthy controls [30] has been demonstrated. These results suggest 
that downregulation of ERβ is found in a pro-inflammatory microenviroment. 
 
Some evidence indicates that E can regulate pathways leading to IL-2 production, which is an 
important factor in determining T-cell tolerance and differentiation [31]. E increases Sp1 
(specific protein 1, transcription factor) expression in human T cells [32], which increases 
expression of the cAMP responsive element modulator (CREM). CREM in turn binds to the IL- 
2 promoter and suppresses the production of IL-2 [32]. This mechanism could potentially 
account for the increased expression of CREM and decreased expression of IL-2 observed in 
female patients with SLE when compared to male patients [33] (Figure 1 A). 
 
The discovery of membrane-associated ERα (mERα) in different cell types, including 
lymphocytes [25], has greatly expanded the understanding of E effects [34]. Rapid signaling by 
17β-estradiol at the membrane level is consistent with the rapid actions of numerous steroids 
acting at often-undefined receptors in a variety of cells [35]. Membrane ERα rapidly activates 
different protein kinase cascades influencing downstream transcription factors to produce non- 
genomic effects; at the same time, it can modulate intracellular ER action through the 
phosphorylation of intracellular ERs and their co-activators [36] (Figure 1 A). 
 
The discovery of the Th17 cell as a bona fide T-cell subset led to a re-kindling of 
interest in this cytokine in the context of autoimmunity. Many, if not  most,  autoimmune 
diseases are now connected in some manner to IL-17 or to the Th17 pathway, indeed, pre- 
clinical studies supporting a role for IL-17 in immune mediated diseases has led to current 
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clinical trials designed to block IL-17, the IL-17 receptor (IL-17R) or its inducers in 
autoimmunity [37]. Interestingly, E/ERα signaling induced an increase of Th17 cells in lymph 
nodes as well as the expression of its correspondent chemokine receptor CCR6 during collagen 
induced arthritis acute phase [38] (Figure 1 A). 
 
All these data highlights the potential role of E and ERs on T cell homeostasis during immune 
mediated diseases. 
 
Estrogens and B cells 
 
 
The effects of sex hormones on the immune system are not limited to T cells [39, 40]. It has 
been demonstrated that E affect different stages of B-cell development and modify the humoral 
response [41-43]. In the bone marrow, E treatment decreases the number of B-cell precursors by 
negatively affecting differentiation, proliferation, and viability of early B-cell precursors. It 
regulates cytoplasmic μ+ bone marrow pre-B cells [42], immunoglobulin (Ig) gene 
rearrangements, and mitotic activity of early B cells [44] (Figure 1 B). ERα has a key role in the 
regulation of B lymphopoiesis and Ig production [45]. E treatment induces B cell homeostasis 
changes, an observation that supports the importance of ERα in the regulation of B cell 
development [46]. ERs and its nuclear receptor family members are involved in the regulation 
of the functional aspects of B cells during class switch recombination. E treatment decreases B- 
cell lymphopoiesis in the bone marrow and this effect can be mediated through either ERα or 
ERβ [26, 47]. The decreased lymphopoiesis has been shown to reflect an estradiol-mediated 
decrease in IL-7 production by bone marrow stromal cells. IL-7 responsive B cell precursors 
were greatly expanded in genetically hypogonadal female mice that have a secondary deficiency 
in gonadal steroidogenesis. E replacement in these mice resulted in a dose-dependent reduction 
in B cell precursors [43] (Figure 1 B). 
 
Since E is a potent inhibitor of B-cell lymphopoiesis, physiological conditions of high E 
production, such as pregnancy, are associated with a reduction in B lymphopoiesis [48, 49]. 
Conversely, ovariectomy leads to increased B lymphopoiesis [50]. 
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In contrast, it has also been described that treatment of women with E or exposure of human 
peripheral blood mononuclear cells (PBMCs) to E lead to significantly higher levels of Igs [51] 
. 17-estradiol acts on mouse splenocytes by increasing IgM and IgE levels [52]. Interestingly, 
E increases the frequency of IgA-producing B cells in μMT-/- mice lacking the μ Ig heavy-chain 
in both bone marrow and spleen, suggesting the existence of an alternative B-cell activation 
pathway in response to E [53]. Short-term E treatment increases the number of Ig producing 
cells both in ovariectomized and intact animals [45]. On the other hand, long-term E exposure 
induces production of antibodies to various self-antigens, such as DNA [54], cardiolipin [55- 
57], phosphatidylserine, and phosphatidylinositol [56], as well as Ig deposition in renal 
glomeruli [58]. These data show that the duration of E exposure has a differential influence on 
B-cell responses (Figure 1 B). 
E seems to promote survival of self-reactive B cells at peripheral checkpoints, possibly via 
upregulation of the prosurvival molecule, apoptosis regulator Bcl-2, the B cell surface molecule 
CD22, and other genes such as shp-1, and vcam-1 [58-62]. The increased survival might occur 
through the binding of ER to E response element (ERE) present in the bcl-2 gene [63] (Figure 1 
B). 
Marginal zone B cells, which are implicated in innate-like B-cell immunity [64], produced high 
level of anti-DNA antibodies, and deletion of CD4+ T cells did not alter their activation after E 
exposure [54]. As might be expected, tamoxifen downregulates the induction of E-modulated 
lupus by preventing B cells from differentiating to a marginal zone B-cell phenotype [41, 54]. 
The recombinant inbred NZM strains of mice develop severe lupus at an early age. It has been 
reported that female NZM/ERα KO mice developed milder lupus diseases with improving 
survival compared to the wild type littermates [65]. However, NZM/ERα KO mice developed 
similar levels of anti DNA IgG and comparable immune complex deposition in the glomerulus 
[65]. Altogether, these data demonstrate that E may modulate B cell homeostasis leading to 
autoimmune development. 
The fact that E impairs B cell lymphopoiesis while increasing Ig producing cells hinder the 
understanding of the immunological effects that occur in different B cell compartment and 
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physiological conditions such as spleen, lymphoid tissues and gestation between others. 
Additionally, given E induce PRL secretion it is likely probable that this last hormone be 
partially involved in E-induced effects [66]. 
 
 
 
Estrogen actions on monocytes and DCs 
 
 
Human monocytes express low levels of ESR1 and ESR2 mRNA [24]. Using flow 
cytometry analysis, it has been reported that 88% of the human peripheral blood monocyte 
population is positive for ER (using a monoclonal antibody that recognizes both isoforms) 
which localizes in the nuclei [67]. Although, the monocytic cell line U937 expressed only ERβ, 
when this cell line differentiates into macrophages with PMA treatment, the ER expression 
profile changed to high expression of ERα with decreased levels of ERβ [67]. In contrast human 
monocyte-derived DCs, which are mainly conventional DCs (cDCs), displayed high levels of 
ESR1 transcripts and low levels of ESR2 mRNA [68, 69]. Although plasmacytoid DCs (pDCs) 
are one of the most important immune cells during SLE pathogenesis, there are few studies 
evaluating the expression of ERs mRNA in them [9, 67, 70]. It has been reported that human 
pDCs express both receptors, ERα and ERβ [68]. Murine cDCs express higher levels of ERα 
than ERβ [71]. Lambert et al showed that cDCs from mice spleen and thioglycolate-elicited 
peritoneal macrophages express ERα mRNA, however neither cell type expressed ERβ [72]. 
Using KO mice, in vitro differentiated DCs from murine bone marrow precursors may also 
express ERα [73]. Recently, it has been reported that E2 may also be able to initiate fast 
responses independently of classical ERs. Human primary monocytes and monocyte-derived 
DCs express the G-protein coupled receptor 30/G-protein E receptor 1, which could bind to E2 
and initiate rapid responses [74]. 
Interestlingly, ERα KO mice display reduced numbers of differentiated DCs from bone 
marrow suggesting E2/ERα modulates GM-CSF mediated differentiation [75]. It is important to 
note that most fetal calf serum preparations possess sufficient amounts of E2 to promote DC 
differentiation [76]. Furthermore, the generation of bone marrow derived DCs is impaired 
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without E2 stimulation [75]. In contrast, it has been reported that the E2/ERα signaling, during 
Flt3 differentiation of pDCs reduces proliferation keeping functional status [71, 77]. ERα 
deficient DCs displayed a decreased capacity of stimulate T cell in the OVA specific transgenic 
T cells [75]. In contrast, E2/ERα ligation induced a mature phenotype with higher levels of co- 
stimulatory molecules CD40 and CD86 and higher expression of IL6 and IL12 in murine 
BMDDCs [75, 78]. In contrast, ERβ KO mice showed normal DCs differentiation suggesting 
that ERβ is not essential for this biological process [75]. 
E increases TLR-ligand activation of DCs via binding to ERα [78]. While CD40 
expression was not affected in ERα KO DCs, the response to CD40L and cytokine production 
were reduced suggesting that DC induced T cell activation is controlled by ERactivation [75]. 
Additionally, E2/ERα signaling in DCs differentiated with GM-CSF promotes the activation of 
Interferon Regulatory Factor 4 (IRF4) which is actively involved in autoimmunity [71]. All 
these data suggest that the sex of the patient should be considered when targeting 
immune responses in cancer or autoimmunity. 
 
 
 
 
Prolactin and T cells 
 
 
In recent years the role of pituitary sex hormones such as PRL has been widely studied and it 
has been observed that in addition to exerting its endocrine control on reproduction, growth, 
metabolism, behavior and immune system, it acts as a cytokine modulating the immune 
response by paracrine and autocrine mechanisms [79-85]. These functions include the capacity 
of PRL to increase the number of immune cells in mammary gland exudates and to enhance the 
chemotaxis effect over T cells, memory T cells, B cells, monocytes, macrophages, neutrophils 
and eosinophils [86], among others. In addition, an association between hyperprolactinemia 
(hyperPRL) and systemic autoimmune diseases (SLE and RA), as well as organ-specific 
autoimmune diseases (DM1, Hashimoto's Thyroiditis and Multiple Sclerosis) has been reported 
[87-90]. However, no data clearly attribute a pathogenic role to PRL in human autoimmune 
pathology. In type 1 diabetes, a disease caused by the autoimmune destruction of pancreatic β- 
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cells, PRL can enhance the efficacy of the anti-CD3 monoclonal antibody therapy to induce the 
remission of diabetes by regulating the mass and function of the β cells [91]. However, this 
action of PRL was not related to the proliferative capacity of T cells [91] but to a trophic action 
of PRL upon -cells. Similarly, in experimental autoimmune encephalomyelitis (EAE), an 
animal model of MS [92-94], the combination of prolactin and a suboptimal dose of 
recombinant murine interferon [β] improved clinical signs of the disease [95]. The role of PRL 
in EAE was also seen in the delay in production of IFN-γ, IL-17A and IL-6 and the T cell 
proliferation induced by myelin Ag in PRL- and PRL-R KO mice [96] (Figure 2 A). These 
results suggest an enhancer effect of PRL in the improvement of both diseases. Prolactin also 
may modulate the suppressor effect of regulatory T (Treg) cells, since prolactin decreases the 
suppressor effect exerted by Treg cells [97] (Figure 2 A). The PRL-R is constitutively expressed 
on Treg cells in healthy individuals and SLE patients, and this expression is higher in SLE 
patients [97]. This point is interesting because both percentage and function of Treg cells are 
decreased in SLE patients compared to healthy individuals [97]. This fact could suggest a 
relationship between the prolactin signaling pathway and the SLE progression. 
 
 
 
 
Prolactin and B cells 
 
 
In addition to the pituitary production and secretion, PRL is produced by the immune system 
cells, which also express PRL receptors (PRL-R) [98] (Figure 2 B). Accordingly, we can expect 
that PRL acts on the immune system via endocrine and paracrine/autocrine pathways [99]. Cells 
of the immune system in the blood and various hematopoietic organs constitutively express 
PRL-Rs [100]. 
Prolactin action is mediated by the PRL-R which exists as a long and a short isoforms; the latter 
resulting from alternative splicing of the intracellular cytoplasmic domain (ICD) [101, 102] . 
The PRL-R is a member of the GH/cytokine receptor super family, which includes receptors for 
growth hormone (GH), leukemia inhibiting factor, leptin, several interleukins and erythropoietin 
[103]. The JAK/Stat pathway is the main signaling pathway used by all members of this 
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receptor family. To activate this pathway, PRL binds to the PRL-R causing the receptors to 
dimerize [104, 105] that leads to the activation of PRL-R-associated JAK2 protein tyrosine 
kinases (PTK). Activated JAK2 then phosphorylates downstream targets on tyrosine residues, 
including the PRL-R ICD, Stat proteins, and other SH2-containing signaling molecules. 
Activated Stats form homo- or heteromeric complexes that translocate into the nucleus, bind to 
a conserved DNA element called interferon (IFN) Gamma Activated Sequence (GAS) and 
regulate target gene transcription. In addition to the JAK/Stat pathway, PRL also activates 
numerous parallel kinase cascades to regulate target gene expression in a tissue- and cell-type- 
specific manner [101] (Figure 2 B). Activation of these cascades modulates several cell 
functions such as differentiation, proliferation, survival, and secretion [106]. B cells treated with 
E increase the expression of PRL-Rs transcripts [107]. In vivo evidence using PRL knockout 
mice revealed that PRL seems to be necessary for enhancing mitogen-induced T-cell 
proliferation under stress conditions, such as thermal injury [108]. Even though E has a critical 
role in the development of SLE, additional studies have demonstrated that prolactin can also 
induce autoimmunity and skew the maturation of autoreactive B cells towards follicular B cells 
[64, 109]. High levels of anti- DNA antibodies and increased mortality was observed when high 
E and high prolactin doses are given to NZB/NZW mice, as compared with mice receiving low 
E and low prolactin doses, or high E and low prolactin doses [110]. Blocking pituitary prolactin 
secretion with the dopamine agonist bromocriptine inhibits E-induced lupus in BALB/c mice 
transgenic for the heavy chain of a pathogenic anti-DNA antibody [111]. This suggests that E 
could modulate SLE through pituitary PRL induction. Additionally it is likely possible that cell 
sensitivity to E(or PRL) mediated by the modulation of hormone receptors may affect lupus 
outcome. However, it could not be rule out that negative selection to self-antigens be 
modulated by E (and/or PRL). 
An important study analyzed the role of the genetic interval Sle3/5, a genomic locus of the 
NZM2410 mouse strain that confers increased lupus sensitivity. When this locus was transferred 
to normal C57/B6 mice (B6.Sle3/5), the mice developed a lupus-like phenotype when treated 
with prolactin [112], highlighting the fact that the Sle3/5 related factors confer sensitivity to the 
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hormone. In a later study, this group demonstrated that the lupus susceptibility locus Sle3, 
confers responsiveness to prolactin and that prolactin-treated DCs from B6.Sle3 mice develop 
IgG specific to DNA [113]. Studies of non-transgenic mice demonstrated that 
hyperprolactinemia interferes with several mechanisms of B-cell induction of tolerance to self- 
antigens [109], suggesting that prolactin, by itself, could impair tolerance checkpoints. 
Interestingly, PRL plays an active role in inhibiting apoptosis of immature B Cells from lupus 
mice. Treatment with anti-IgM F(ab′)2 antibody to induce cross-linking of the BCR, a step that 
mimics self-antigen recognition, produces a significant decrease in the viability and increase in 
apoptosis of immature B-cells from wild type C57BL/6 mice and lupus MRL/lpr mice [114]. 
However, preincubation with prolactin prevented the effect of the anti-IgM treatment in the 
lupus MRL/lpr mice but had no effect on the C57BL/6 mice [114] (Figure 2 B). Thus, prolactin 
may increase the severity of the disease in lupus prone subjects by promoting the maturation 
and survival of self-reactive B cells. 
Another important study reported that SLE patients presented increased circulating PRL levels 
when compared to normal subjects that correlated positively with anti-double-stranded DNA 
autoantibody production. Of note, PRL concentration was reduced during disease remission, 
indicating that PRL levels may predict disease severity in SLE patients [115, 116]. Increased 
PRL levels have also been reported in association with rheumatoid arthritis, systemic sclerosis 
and others autoimmune diseases [117, 118]. These findings have led to the proposal of PRL as a 
novel biomarker for autoimmune diseases [119]. Similarly, MS patients have significantly 
elevated levels of PRL irrespective of the stage of the disease and PRL increases the production 
of anti-myelin IgG in vitro [107]. Activation of B cells in the presence of PRL enhanced the 
secretion of BAFF and Bcl-2, and B cell receptor threshold decreased displaying an increase in 
cell activation and proliferation [107]. It should be pointed out that a case report shows that 
treating a prolactinoma resulted in the remission of a multiple sclerosis disease condition, which 
had developed when the patient´s PRL levels were very high [120]. 
 
 
 
Prolactin and macrophages 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Prolactin regulation of monocyte and macrophage functions is suggested by the presence of 
PRL-R in these cells [121, 122]. Different studies show that macrophages exposed to PRL 
secrete higher amounts of IFN-, IL-1β, IL-12, chemokines like macrophage inflammatory 
protein (MIP)-1α, monocyte chemoatractant protein (MCP)-1 and IFN-gamma-inducible protein 
(IP)-10, as well as reactive oxygen species [121-123]. Additionally, PRL has been shown to 
play a cooperative role in the production of pro-inflammatory cytokines such as IL-6 and IL-12 
in response to CD40L and TNF [124]. In rheumatoid arthritis and psoriatic arthritis patients, 
PRL-R expression is significantly higher in sinovial tissue compared with healthy individuals 
[124]. Furthermore, IFN-- and IL-10-treated macrophages showed an increased expression of 
PRL-R compared to control cells [124]. Thus, prolactin may be part of a positive feedback loop 
in macrophages, stimulating the production of inflammatory factors, that in turn stimulate PRL- 
R expression, resulting in exacerbated inflammation. 
 
 
 
Prolactin and DCs 
 
As discussed above, PRL has been associated to diverse autoimmune diseases including lupus 
pathogenesis in human and murine models but its role on DCs has been poorly studied [113, 
125]. It has been reported that PRL profoundly modulates DC phenotype [126]. PRL-R is 
expressed in the majority of thymic DCs [127]. It has been shown that PRL promotes a mature- 
like phenotype in murine splenic DCs (cDCs and pDCs), increasing the expression of MHC-II 
and CD40 molecules [128]. Furthermore, in these cells, PRL increased the production of several 
pro-inflammatory cytokines such as IL-6 and IL-12 [128]. Similarly, PRL synergized with GM- 
CSF to promote the differentiation of human-primary monocytes into cDCs [129]. Nevertheless, 
PRL-treated thymic DCs displayed an increase in the immunogenicity capacity in mixed 
leukocyte reaction assays, cell surface expression of CD80 and MHC molecules, and production 
of IL-12, TNFα e IL-1β [127, 129, 130]. DCs exposed to high PRL concentrations show an 
increased antigen-presenting activity that may be of significance in the initiation of the immune 
response   against   MHC-presented   self-antigens   and   may   explain   the   association   of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
hyperprolactinemia with autoimmune diseases [130]. In the B6.Sle3/5 mice, in which PRL 
induces a lupus-like disease [131], the hormone increases CD80 expression on cDCs [113]. 
Additionally, adoptive transfer of DCs (cDCs and pDCs) from PRL-treated B6.Sle3/5 mice to 
wild type recipients promotes the development of lupus-like disease, increasing DNA-reactive 
B cells and suggesting that PRL may promote rupture of the immune tolerance to DNA [113]. 
There is a strong relationship between DCs and Treg cells which is reflected in the higher 
production of IL-6 and IL-23 in vitro and in vivo by DCs when these cells are exposed to the 
increased prolactin levels induced by stress [126]. This higher production of cytokines by the 
DCs plays a critical role modifying Treg phenotypes [126]. 
 
 
 
Progesterone and immune cells 
 
Progesterone (P), a sex steroid hormone, plays an immune modulator role by binding with 
specific receptors. The presence of membrane progesterone receptors (mPRs) has been 
demonstrated in human peripheral blood T cells (PAQR7, PAQR8 y PAQR5 and PGRMC1) 
[132] and in the resident T cell population of bovine corpus luteum [133] (Figure 3 A). 
Intracellular progesterone receptors (iPR) have been detected in TCD4
+ 
cells, that suppress T 
cell dependent (TD) antibody responses [134]. However, iPR KO mice displayed a healthy 
spleen cell homeostasis and normal levels of circulating IgG suggesting that this receptor may 
modulate immune cells only in the presence of P [134]. In contrast, iPR KO mice showed an 
increased IFN-production by spleen cells [134] (Figure 3 A). 
 
P is a potent inductor of Treg activity, increasing naive T cells differentiation into 
FoxP3
+
T cells that are more stable under inflammatory conditions [135] (Figure 3 A). At high 
concentrations, P inhibits differentiation of bone marrow murine DCs to CD11b
+ 
CD11c
+ 
and 
reverses the differentiation induced by E [136]. Monocytes from newborn umbilical blood 
expressed  higher  levels  of  mPR  than  adult  peripheral  blood  monocytes,  and  were  more 
susceptible to P leading to a decreased production of pro-inflammatory cytokines, such as TNF 
and IL-6 [137]. In canine neutrophils, it has been reported that P decreases phagocytic activity 
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and oxidative burst [138]. In humans, some authors have shown that mPRα expressed in 
peripheral blood T cells during pregnancy, is mainly involved in immune response regulation, 
generates fetal protection and impairs fetal complications [139]. 
 
For the treatment of premature labor, which has a high rate of perinatal mortality, some authors 
emphasize the use of P. It has been reported that peripheral blood CD4
+ 
Treg from women with 
preterm labor, increase significantly after P administration when compared with a nulliparous 
group [139]. Moreover, Bianchi et al.; demonstrated that progesterone participates in the 
establishment of the tolerogenic state during gestation, impairing the expression of the enzyme 
indoleamine2,3-dioxygenase (IDO) in CD4
+ 
and dendritic cells [140] (Figure 3 A). In rats, 
during the stages where progesterone levels are high, like diestrus or metaestrus, DCs were 
more susceptible to the action of this hormone through binding to PRs [141]. Strikingly, P 
impairs the expression of several immune factors such as MHC class II, co-stimulatory 
molecules, production of TNF and IL-1 and reduces T cell priming in in vivo and in vitro assays 
[141] (Figure 3 A). 
Interestingly, Pg also has indirect effects over B cells. It has been reported that Pg treated 
endometrial stromal cells decreased the expression of the co-stimulatory molecules CD80 and 
CD86 on B cells [142]. Also, Pg decreases transcription of activation-induced deaminase m 
RNA, a crucial molecule in Ig diversification [143] (Figure 3 B). 
Thus, the effects of P on immune cells are mainly suppressive, in particular during pregnancy, 
in which this hormone plays a pivotal role towards preservation of the growing fetus by 
preventing its rejection by the maternal immune system, along with the maintenance of a 
quiescent uterus. 
 
 
 
 
Progesterone and autoimmunity 
 
 
P plays an important role in the regulation of immune mechanisms associated with autoimmune 
diseases such as SLE, Rheumatoid Arthritis and Experimental Autoinmune Encephalomyelitis 
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in animals (EAE) [144, 145]. During EAE, it has been reported that P administration decreases 
TNF-α, IL-2, and IL-17 secretion, reduces cellular infiltration in the spinal cord, increases 
myelinization and clinically reduces signs of illness [145]. Furthermore, some authors 
established that this hormone reduces the risk of SLE by antagonizing some E2 effects [141, 
146]. Addittionally, Wong et al., have reported that aged female lupus prone mice made PR KO 
displayed an increase in IgG anti DNA autoantibodies, leading to glomerular immune complex 
deposition and concomitant kidney damage [144]. Additionally PR deficiency decreases splenic 
Tregs and increases T follicular helper and IFN-  production in these aged females [144] 
(Figure 3 A). Interestingly, PR deficient DCs showed an increased expression of the co- 
stimulatory molecule CD86 [144]. Similarly, continuous medroxyprogesterone acetate 
administration to female NZB/NZW mice decreased anti DNA IgG, improved survival, 
decreased glomerulonephritis and proteinuria, and lowered the expression of CD86 on DCs 
[147] (Figure 3 B). Unexpectedly, these authors reported that medroxyprogesterone acetate 
increased the expression of CD40 on B cells which is crucial for germinal center reaction [147] 
(Figure 3 B). In conclusion, P inhibits immune cell activation improving immunological status 
during autoimmunity. 
 
Conclusions 
 
 
In summary, E and PRL actions on the immune system are mostly stimulatory, promoting its 
activation and the induction of autoimmunity, while P actions are mainly suppressive, 
repressing autoimmunity and most importantly, rejection of the embryo by the maternal immune 
system. This may be another instance where the action of E and prolactin are opposed or 
prevented by progesterone, as observed in other physiological situations such as mammary 
gland function and some instances of the regulation of hormone secretion and actions. 
The capacity of sex steroids and prolactin to affect not only the differentiation, regulation, and 
responsiveness of B and T cells, but also immune messengers, such as pro-inflammatory 
cytokines, add layers of complexity to the interactive molecular and cellular events that occur in 
inflammatory  and  autoimmune  diseases.  Intense  studies  are  currently  delineating  how  sex 
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hormones impact the immune system. Deciphering the multi-faceted influences of sex 
hormones on the responsiveness of B lymphocytes could be critical in elucidating key 
pathogenic mechanisms and provide novel therapeutic strategies for those pathologies where the 
immune system is involved. 
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Figure 1 
 
Estrogen, estrogen receptor, T cells and B cells. A, a significant lower expression of ERβ in T 
cells from patients with SLE compared with healthy controls is reported. Estradiol (E) increases 
Sp1 (specific protein 1, transcription factor) expression in human T cells which increases 
expression of the cAMP responsive element modulator (CREM). CREM in turn binds to the IL- 
2 promoter and suppresses the production of IL-2 decreased expression of IL-2 observed in 
female patients with SLE when compared to male patients. E/ERα signaling induced an increase 
of Th17 cells in lymph nodes as well as the expression of its correspondent chemokine receptor 
CCR6 during collagen induced arthritis acute phase. E treatment decreases the number of B-cell 
precursors by negatively affecting differentiation, proliferation, and viability of early B-cell 
precursors amd Ig production. E seems to promote survirval of self-reactive B cells at peripheral 
checkpoints, possibly via upregulation of the prosurvival molecule, apoptosis regulator Bcl-2, 
the B cell surface molecule CD22, and other genes such as shp-1, and vcam-1. 
 
Figure 2 
 
Prolactin, prolactin receptor, T cells and B cells. A, PRL is produced by the immune system 
cells, which also express PRL receptors (PRL-R). PRL acts on the immune system via 
endocrine and paracrine/autocrine pathways. Prolactin action is mediated by the PRL-R which 
exists as a long and a short isoforms; the latter resulting from alternative splicing of the 
intracellular cytoplasmic domain leading to JAK/Stat pathway signaling. The role of PRL in 
EAE was also seen in the delay in production of IFN-γ, IL-17A and IL-6 and the T cell 
proliferation induced by myelin Ag in PRL and PRL-R KO mice. Prolactin also may modulate 
the suppressor effect of regulatory T (Treg) cells, since prolactin decreases the suppressor effect 
exerted by Treg cells. B, High levels of anti- DNA antibodies and increased mortality was 
observed when given high E and high prolactin doses to NZB/NZW mice. Activation of B cells 
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in the presence of PRL enhanced the secretion of BAFF and Bcl-2 production. When B cells 
were stimulated with PRL, BCR threshold decreased displaying an increase in cell activation 
and proliferation. 
 
 
 
Figure 3 
 
Progesterone, PRs, T and B cells. A, the presence of membrane progesterone and intracellular 
receptors (mPRs and iPR) has been demonstrated in human T cells. P decreased T cell 
activation and priming. P is a potent inductor of Treg FOXP3 activity. iPR KO mice showed an 
increased IFN-production by spleen cells. B, on B cells, P decreased the expression of the co- 
stimulatory molecules CD80 and CD86 on B cells. P administration on female NZB/NZW mice 
decreased anti DNA IgG. Pg decreases transcription of activation-induced deaminase m RNA, a 
crucial molecule in Ig diversification. 
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